# Novel peptide for enhancing diabetic wound healing

> **NIH NIH R44** · SCARLESS LABORATORIES, INC. · 2021 · $258,589

## Abstract

PROJECT SUMMARY/ABSTRACT
Diabetes Mellitus (DM), a metabolic disorder characterized by defective insulin signaling and elevated blood
glucose, has become a public health epidemic with half of the US population diagnosed with either DM or pre-
diabetes. One of the most common and devastating sequelae of uncontrolled DM is the development of chronic
non-healing wounds. An estimated 25% of diabetic patients develop chronic non-healing ulcers in their lifetime
that, given the poor vascularity and immunodeficiency associated with diabetes, are highly susceptible to
infection and frequently result in limb amputation. DM is currently the seventh leading cause of death in the U.S.
Current management primarily focuses on controlling wound bioburden to promote wound healing, which
includes pressure off-loading, antimicrobial medications and dressings, judicious wound care, and optimization
of lifestyle factors. However, complete wound closure is complicated by impairment of cellular migration and
function in DM wounds. Therefore, there is a pressing need to develop novel therapeutic methods for diabetic
wounds that directly restore the molecular and cellular processes required to promote proper cutaneous repair.
 Injuries in diabetic patients often persist and progress. Chronic DM causes significant alterations to several
physiologic wound healing mechanisms that impair timely cell infiltration/migration, granulation tissue formation,
and wound contraction. Based on more than 20 years of research on wound healing management, we have
developed a technologically innovative fibromodulin (FMOD)-based amino acid peptide sequence, SLI-F06, that
markedly stimulates fibroblast and endothelial cell migration and myofibroblast differentiation/contraction to
promote timely wound closure. Previously, we demonstrated that SLI-F06 significantly promotes acute wound
healing without eliciting any adverse effects in preclinical animal studies at maximal feasible dosing as well as
in ongoing Phase 1/2a clinical trial targeting acute wound healing. Excitingly, we have shown that repeated SLI-
F06 administration significantly accelerates diabetic wound closure in a mouse model (NONcNZO10/LtJ) that
closely simulates human type 2 DM. The goal of the current Fast-track SBIR application is to obtain the key
preclinical efficacy and mechanism of action data for SLI-F06 as a repeatedly administered, locally
applied therapeutic for diabetic wounds for expanding the clinical indication of SLI-F06. Overall, this
proposal will accomplish key efficacy and mechanism of action (MOA) objectives to expedite commercialization
of SLI-F06-based therapy for diabetic wounds. This product can significantly improve the quality of life of diabetic
patients suffering from chronic wounds that can lead to amputations and death.

## Key facts

- **NIH application ID:** 10383864
- **Project number:** 1R44DK131648-01
- **Recipient organization:** SCARLESS LABORATORIES, INC.
- **Principal Investigator:** Chia Soo
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $258,589
- **Award type:** 1
- **Project period:** 2021-09-24 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10383864

## Citation

> US National Institutes of Health, RePORTER application 10383864, Novel peptide for enhancing diabetic wound healing (1R44DK131648-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10383864. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*